New cocktail of cancer drugs shows promise in early lymphoma trial
NCT ID NCT01829568
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a combination of three drugs—rituximab, lenalidomide, and ibrutinib—in people with untreated follicular lymphoma. The goal is to find the safest dose and see how well patients tolerate the mix. The study includes 33 participants with stage II to IV disease. If successful, this could lead to a more effective first treatment option for this slow-growing blood cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rituximab, lenalidomide, and ibrutinib
What this could lead to
If it works, this could point toward a more effective initial treatment for follicular lymphoma that may help control the disease longer.
What could go wrong
This is a very early phase I trial with only 33 people, so the main goal is safety, not proof of effectiveness. The combination may cause significant side effects and may not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE III GRADE 1 FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
NYP/Weill Cornell Medical Center
New York, New York, 10065, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States